20


Characterised compound libraries to accelerate drug discovery


Maximising sensor performance: Choosing the right lens


Resolve Optics has published a white paper that explores how to select the ideal lens for your camera or sensor to achieve peak imaging performance. While lens quality is critical, resolving power is ultimately limited by physics, and it’s a common misconception that a lens simply needs to match or exceed a sensor’s Nyquist resolution to deliver optimal results.


The paper explains why understanding Nyquist resolution matters, how lens performance can be affected by Moiré patterns and aliasing, and why a digital sensor can only sample an analogue signal up to half its Nyquist rate. It also discusses how custom lens development can improve the performance of image intensifiers and other specialised imaging equipment.


To access the white paper, ‘Sensor Resolution versus Lens Resolution’, or to discuss custom lens solutions, contact Resolve Optics.


More information online: ilmt.co/PL/8e86


Amsbio provides researchers with access to an extensive portfolio of more than 325,000 fully characterised chemical compounds designed to streamline drug discovery and development. Covering everything from individual inhibitors, agonists, and natural products to ready-to-screen libraries, these high-quality and cost- effective reagents are suited to both academic and industrial applications.


With a focus on areas such as apoptosis, autophagy, cell cycle regulation, immunology, and signalling cascades, the collection includes over 20,000 small molecule inhibitors and agonists offering excellent membrane permeability, high chemical stability, and broad utility in both in vitro and in vivo studies.


Amsbio’s compound libraries, widely adopted by pharmaceutical and biotech high-throughput screening teams, encompass more than 800 curated sets. These include focused bioactive libraries, fragment libraries, natural product libraries, and diversity sets, each designed to probe specific targets or chemical space. All compounds are supplied with stringent quality assurance data - including HNMR, HPLC, and GC profiles - to confirm structural accuracy and purity.


The range also features over 16,000 natural products, such as flavonoids, alkaloids, terpenoids, coumarins, and saponins, supporting research across oncology, infectious disease, neurobiology, and metabolic disorders. In addition, Amsbio offers an expanding collection of PROTAC (Proteolysis Targeting Chimera) molecules. By leveraging the ubiquitin–proteasome system to selectively degrade proteins, PROTACs often demonstrate superior target engagement compared with traditional inhibitors.


Available in a variety of pack sizes to suit different research needs, Amsbio’s comprehensive offering of pre- characterised compounds are readily searchable by CAS number, name, and product code.


More information online: ilmt.co/PL/kox3 65769pr@reply-direct.com


65963pr@reply-direct.com


Maximum capacity, minimal footprint: Rethinking autoclave design for modern research labs


Laboratories often assume high-capacity autoclaves must be large, front-loading units that dominate floor space. For many research applications, this is unnecessary. The main requirement is vertical clearance for tall vessels, not expansive horizontal volume.


Priorclave, a UK-based manufacturer renowned for precision-engineered autoclaves, has addressed this need with its top-loading designs. These units offer substantial chamber capacity while maintaining a compact footprint - typically no wider or deeper than one metre. This enables tall loads to be processed efficiently while reducing energy, water use, acquisition costs, and improving throughput.


Among Priorclave’s top-loading offerings, the EV200-SMART stands out with a vertically oriented 200-litre pressure vessel. Engineered for demanding research environments, this autoclave integrates advanced sterilisation features, including: Automatic timed free-steaming; Forced air cooling; Multi-stage pre-cycle vacuum with interspersed heating; Vacuum-assisted drying ; Pulsed free-steaming to enhance vacuum efficiency.


These features ensure thorough sterilisation of complex and porous loads, making the EV200- SMART ideal for microbiology, molecular biology, and bioprocessing workflows.


The EV200-SMART’s pressure vessel is insurance-approved with a 10-year warranty. Thermal and pressure interlocks prevent access above 80°C or 0.2 bar. All Priorclave autoclaves are equipped with the proprietary Tactrol®


3 controller, offering intuitive, glove-friendly operation and fully


programmable cycles. The unit’s epoxy-coated panels and frame are treated with a long-lasting antimicrobial agent effective against all known bacteria and fungi, including MRSA - supporting aseptic conditions and simplifying cleaning protocols.


Recognising that not all labs require a 200-litre chamber, Priorclave offers the EV-SMART series in 100-litre and 150-litre models as well. For facilities with less complex sterilisation needs, a Basic edition is also available - omitting vacuum features while retaining core performance and safety standards.


Priorclave is one of the few autoclave manufacturers globally to maintain complete control over its supply chain. All principal components are fabricated in-house at their London facility, including pressure vessels produced using a proprietary seam welding system. This commitment to craftsmanship ensures long-term durability and consistent performance - hallmarks of the brand’s reputation.


Priorclave continues to set the standard for autoclave innovation - delivering high-capacity sterilisation without compromising space, safety, or sustainability.


More information online: ilmt.co/PL/jYeO 65969pr@reply-direct.com Automated synthesiser streamlines peptide production


Vapourtec has unveiled the Peptide-Builder, a fully automated, high-throughput benchtop synthesiser designed to transform solid-phase peptide synthesis (SPPS). Compact and intuitive, it streamlines workflows while cutting costs and waste.


At the heart of the system is Vapourtec’s Variable Bed Flow Reactor (VBFR) technology, which increases efficiency, reduces solvent and reagent consumption, and delivers high-purity, high-yield peptides.


Developed in collaboration with peptide chemists, Peptide-Builder is the smallest high-throughput system of its kind, producing more peptides per square metre than any other platform. It supports flexible scales from 0.05 to 1 mmol and is compatible with widely used resins.


Operating sequentially, it can synthesise a GLP-1 analogue in under four hours, or up to sixteen analogues unattended over a weekend. User-friendly software - created with input from a major pharma partner - allows scientists to simply enter a sequence, press ‘start’ and walk away.


The system requires fewer than three equivalents of amino acid and handles both linear and branched peptides, including automated side-chain addition. Each run generates a detailed report that tracks aggregation events and Fmoc deprotection, offering valuable insights for tackling challenging syntheses.


Dr Manuel Nuño commented: “VBFR technology is a true game-changer, boosting efficiency, streamlining workflows, providing unique in-process data, and reducing space requirements without compromising performance.”


More information online: ilmt.co/PL/Nwbl 65698pr@reply-direct.com


LABMATE UK & IRELAND - NOVEMBER 2025


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44